Shots:

• The company has reported the initiation of the first clinical trial of REGN-COV2. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients- non-hospitalized symptomatic COVID-19 patients- uninfected people that are at high risk of exposure and uninfected people with close exposure to a COVID-19 patient
• The first two adaptive P-I/II/III studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized & non-hospitalized patients with COVID-19. The P-I & P-II portion will focus on virologic and safety endpoints & clinical endpoints respectively
• Data from the P-I/II studies will be used to refine the EPs and will determine the size for P-III studies while BARDA has funded the REGN-COV2's preclinical development and pre/clinical manufacturing. Additionally- Regeneron has developed REGN-EB3- a novel triple antibody treatment for Ebola which is under FDA’s regulatory review

Click here to read full press release/ article | Ref: Regeneron | Image: Regeneron

Related News: Regeneron to Initiate COVID-19 Antibody Program in Early Summer